Download Print Send a summary of this page to someone via email.

Documents Referenced in The Cancer Letter

2012 Volume 38

  • The NCI Memo circulated before the cancer center directors' April 19 retreat (The Cancer Letter, May 11, 2012).
  • An outline of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • A draft of the 2013 CCSG Guidelines (The Cancer Letter, May 11, 2012).
  • A summary of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • Director Cullen's letter to NCI's Weiss (The Cancer Letter, May 11, 2012).
  • The letter sent by 11 cancer center directors to Weiss (The Cancer Letter, May 11, 2012).
  • The complaint filed by attorneys representing Timothy Kinsella against Amelia Weber (The Cancer Letter, April 20, 2012).
  • The Opposition to Seal, sent by attorneys representing Amelia Weber (The Cancer Letter, April 20, 2012).
  • Urorad Healthcare's FAQ sheet regarding developing IMRT centers (The Cancer Letter, April 13, 2012).
  • TwinCrest Group's flyer to urology practices offering in-office pathology (The Cancer Letter, April 13, 2012).
  • Part one of a collection of files containing Craig Thompson's Motion to Dismiss, filed as part of the Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • Part two of a collection of files containing Thompson's Motion to Dismiss (The Cancer Letter, March 23, 2012).
  • Agios Pharmaceuticals' Motion to Dismiss, filed against Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • UPenn's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • Attachments to UPenn's complaint (The Cancer Letter, March 9, 2012).
  • The Abramson Institute's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Policies document (The Cancer Letter, Feb. 3, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Agreement document (The Cancer Letter, Feb. 3, 2012).
  • FDA's letter to the Division of Medical Oncology, Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • Letter to CDER from the Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • FDA Establishment Inspection Report, January 2011 (The Cancer Letter, Jan. 27, 2012).
  • NVCI co-founder Heather Murren's declaration in bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • Restructuring consultant George Pillari's declaration in NVCI's bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • The Cancer Letter's interview with Robert Young, former NCCN chairman: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
  • The Cancer Letter's interview with Catherine Harvey, NCCN's first executive director: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
  • The March 15, 1996, and Jan. 24, 1997, issues of The Cancer Letter (The Cancer Letter, Jan. 13, 2012).

2011 Volume 37

  • Anil Potti's application and letters of recommendation to the South Carolina licensure board (The Cancer Letter, Dec. 9, 2011).
  • Duke University's letter to the president of the North Carolina Medical Board (The Cancer Letter, Dec. 9, 2011).
  • NC Medical Board Reprimands Former Duke Doctor Anil Potti. The text of the consent decree.  
  • The email sent by Jerome Yates, former American Cancer Society VP for research, regarding the society's restructuring (The Cancer Letter, Nov. 18, 2011).
  • The TREAT Act, a model bill proposing two new options for FDA approval (The Cancer Letter, Nov. 18, 2011).
  • NCI CTEP's RFA Presentation to the Board of Scientific Advisors (The Cancer Letter, Nov. 11, 2011).
  • Exhibit E: Spreadsheets showing the overfill of Aranesp compared to Procrit, in US & Westmoreland vs. Amgen (The Cancer Letter, Oct. 28, 2011).
  • The whistle-blower lawsuit of US & Westmoreland vs. Amgen Inc. (The Cancer Letter, Oct. 28, 2011).
  • The US Preventive Services Task Force Systematic Review Of Evidence Draft Paper, via Annals of Internal Medicine (The Cancer Letter, Oct. 7, 2011).
  • The jointly filed lawsuit against Duke University, Duke University Health System, Potti, Nevins, et al. (The Cancer Letter, Sept. 9, 2011).
  • The filed lawsuit of Joyce Shoffner vs. Duke University, et al. (The Cancer Letter, Sept. 9, 2011).
  • Citizen Oncology Foundation's analysis of the drug shortage (The Cancer Letter, Sept. 9, 2011).
  • FDA CDER's Post-Hearing Submission against Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
  • Genentech's Post-Hearing Submission in favor of Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
  • The letter to Varmus and Doroshow from advocates for the Children's Oncology Group (The Cancer Letter, July 8, 2011).
  • The letter to Varmus and Doroshow from patients involved in the adult cancer cooperative groups (The Cancer Letter, July 8, 2011).
  • Aug. 5, 2005 issue of The Cancer Letter (The Cancer Letter, July 1, 2011).
  • Claudia Henschke's affadavit used in class action suits against Philip Morris USA (The Cancer Letter, June 24, 2011).
  • The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, June 24, 2011).
  • The caBIG Program Update presented to the Board of Scientific Advisors (The Cancer Letter, June 24, 2011).
  • The First CALGB Protocol (The Cancer Letter, June 17, 2011).
  • The GAO's Decision to deny Velos' request for reconsideration (The Cancer Letter, June 17, 2011).
  • FDA CDER's Summary of Arguments supporting withdrawal of Avastin's breast cancer indication (The Cancer Letter Special Issue, May 27, 2011).
  • Genentech's Pre-Hearing Summary of Evidence in support of maintaining Avastin's accelerated approval (The Cancer Letter Special Issue, May 27, 2011).
  • The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, April 29, 2011). 
  • The 2009 tax filing by Henschke's Foundation for Lung Cancer: Early Detection, Prevention & Treatment (The Cancer Letter, April 29, 2011). 
  • Velos protests NCI's decision to award a contract related to caBIG to Medidata (The Cancer Letter, April 22, 2011).
  • The FDA's Avastin Decision Memorandum (The Cancer Letter, April 15, 2011).
  • The CMS Provenge Decision Memo (The Cancer Letter, April 1, 2011).
  • The Duke University official account of the history of the scandal (The Cancer Letter, April 1, 2011).
  • The press release announcing the merger of ACOSOG, CALGB and NCCTG.
  • BSA caBIG Assessment (The Cancer Letter, March 4, 2011).
  • Response to CL Questions (The Cancer Letter, March 4, 2011).
  • UPDATED Response to CL Questions (The Cancer Letter, March 4, 2011).
  • Jeremy Berg - SMRB Comments (The Cancer Letter, Feb. 25, 2011).
  • Velos GAO Decision 11-28-2008 (The Cancer Letter, Feb. 25, 2011).
  • Velos GAO Decision 12-14-2009 (The Cancer Letter, Feb. 25, 2011).
  • Velos Letter to Varmus (The Cancer Letter, Feb. 25, 2011).
  • Original Award Doc to Velos from DOI (The Cancer Letter, Feb. 25, 2011).
  • NCI Medidata Award Notification (The Cancer Letter, Feb. 25, 2011).
  • Notice of Cancellation 12-15-10 (The Cancer Letter, Feb. 25, 2011).
  • NCI - Velos Selected for Award Powerpoint (The Cancer Letter, Feb. 25, 2011).
  • The letters from HHS to Congress regarding NCATS and NCRR (The Cancer Letter, Feb. 11, 2011).
  • A transcript of the NIH town hall conference call with NCRR stakeholders (The Cancer Letter, Feb. 11, 2011).
  • A transcript of the NIH town hall conference call with CTSA principal investigators (The Cancer Letter, Feb. 11, 2011).
  • The SMRB final report of their Dec. 7 meeting, voting to approve the plan for NCATS (The Cancer Letter, Feb. 11, 2011).
  • GOG White Paper argues for keeping the group separate (The Cancer Letter, Feb. 4, 2011). 
  • Duke pre-IDE filing on Lung Metagene Score (The Cancer Letter, Jan. 28, 2011).
  • FDA response to Duke pre-IDE filing (The Cancer Letter, Jan. 28, 2011).
  • Internal Duke document listing trials and their regulatory status (The Cancer Letter, Jan. 28, 2011).
  • Lisa McShane Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
  • Robert Becker Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
  • New Timeline of the Duke Scandal; Lung Metagene Score data (The Cancer Letter, Jan. 14, 2011).
  • Internal NCI documents (zip files 1, 2 and 3) related to the Duke genomics controversy (The Cancer Letter, Jan. 7, 2011).

2010 Volume 36

  • NIH response to Sen. Charles Grassley on sponsored travel by NCI scientists (The Cancer Letter, Dec. 3, 2010).
  • NCI-funded CISNET model presented by Harvard researchers predicting outcome of National Lung Screening Trial (The Cancer Letter, Nov. 26, 2010).
  • Sen. Charles Grassley letter to NIH Director Francis Collins and NCI Director Harold Varmus on "sponsored travel" by NCI scientists (The Cancer Letter, Oct. 29, 2010.)
  • NCI letter of Oct. 15, 2010 on carboplatin dosing, referenced in The Cancer Letter, Oct. 22, 2010.
  • NCI Letter of Oct. 1, 2010, "Action Letter for Protocols Sponsored by the National Cancer Institute That Use Carboplatin." Referenced in The Cancer Letter, Oct. 8, 2010.
  • Documents on Avastin referenced in Sept. 3, 2010, issue of The Cancer Letter: Howard Burris letter; AdvancedBC.org letter; advocacy groups' letter to FDA; Kathy Miller letter to ES103 investigators; Gabriel Hortobagyi email; National Breast Cancer Coalition letter to FDA.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 30, 2010: Potti's bio submitted to Department of Defense.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 23, 2010: Letter by 33 biostatisticians to NCI Director Harold Varmus. Letter by American Cancer Society Chief Medical Officer Otis Brawley to Duke University. A list of Potti's technologies available for licensing from Duke. More detailed description of one of these technologies.
  • Duke scientist Anil Potti's different CVs: version 1, version 2, and version 3. His University of North Dakota Residency application, and a page from a Duke brochure listing his claimed Rhodes scholarship. The Cancer Letter, July 16, 2010.
  • City of Hope dispute with for-profit physician group reading materials (.zip file), referenced in The Cancer Letter, May 28, 2010.
  • Entertainment Industry Foundation's 2008 IRS Form 900, referenced in The Cancer Letter, May 21, 2010.
  • Documents on Duke University genomics research: Duke report and email obtained by The Cancer Letter; comments by biostatisticians on the report (The Cancer Letter, May 14, 2010).
  • Letters by American Society of Clinical Oncology and the Massachusetts Hospital Association protesting Mass. Blues restrictions on ESAs (The Cancer Letter, April 9. 2010).
  • Analysis of industry-sponsored phase I studies prepared by The Cancer Letter for article in March 26, 2010, issue.
  • NCI concept statements: Barrett's Esophagus Translational Research Network and Commercial Application and Use of Emerging Molecular Analysis Technologies (SBIR) (The Cancer Letter, March 19, 2010).
  • NCI concept statement: Clinical Proteomic Technologies for Cancer (The Cancer Letter, March 12, 2010).
  • Documents (zip file) in Allergan lawsuit against FDA over off-label use promotion (The Cancer Letter, Jan. 15, 2010).